Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Jun 19. pii: nyz186. doi: 10.1093/neuros/nyz186. [Epub ahead of print] No abstract available.

PMID:
31215634
2.

Occurrence of Antithrombotic Related Adverse Events in Hospitalized Patients: Incidence and Clinical Context between 2008 and 2016.

Moesker MJ, Schutijser BCFM, de Groot JF, Langelaan M, Spreeuwenberg P, Huisman MV, de Bruijne MC, Wagner C.

J Clin Med. 2019 Jun 12;8(6). pii: E839. doi: 10.3390/jcm8060839.

3.

Barriers to Accrual and Enrollment in Brain Tumor Trials.

Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS, Chang SM, Arons D, Oliver K, Verble K, Musella A, Willmarth N, Alexander BM, Bates A, Doherty L, Galanis E, Gaffey S, Halkin T, Friday BE, Fouladi M, Lin NU, Macdonald D, Mehta MP, Penas-Prado M, Vogelbaum MA, Sahebjam S, Sandak D, van den Bent M, Weller M, Reardon DA, Wen PY.

Neuro Oncol. 2019 Jun 7. pii: noz104. doi: 10.1093/neuonc/noz104. [Epub ahead of print]

PMID:
31175826
4.

Wheelchair Mobility Confidence Scale for Dutch youth using a manual wheelchair.

Sol ME, Bloemen MAT, Verschuren O, Rushton PW, Visser-Meily JMA, de Groot JF.

Disabil Rehabil Assist Technol. 2019 Apr 23:1-8. doi: 10.1080/17483107.2019.1604832. [Epub ahead of print]

PMID:
31012747
5.

Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center.

Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF.

Eur J Cancer. 2019 May;112:83-93. doi: 10.1016/j.ejca.2019.02.007. Epub 2019 Apr 2.

PMID:
30951926
6.

Utrecht Pediatric Wheelchair Mobility Skills Test: Reliability, Validity, and Responsiveness in Youths Using a Manual Wheelchair.

Sol ME, de Groot JF, Zwinkels M, Visser-Meily JMA, Kruitwagen CLJJ, Verschuren O.

Phys Ther. 2019 Apr 2. pii: pzz061. doi: 10.1093/ptj/pzz061. [Epub ahead of print]

PMID:
30939199
7.

Prospective Clinical Sequencing of Adult Glioma.

Zheng S, Alfaro-Munoz K, Wei W, Wang X, Wang F, Eterovic AK, Shaw KRM, Meric-Bernstam F, Fuller GN, Chen K, Verhaak RG, Mills GB, Yung WKA, Weathers SP, de Groot JF.

Mol Cancer Ther. 2019 May;18(5):991-1000. doi: 10.1158/1535-7163.MCT-18-1122. Epub 2019 Mar 29.

PMID:
30926639
8.

Commentary on "Cardiopulmonary Exercise Test Using Arm Ergometry in Children With Spina Bifida: A Prediction Model for O2peak.

de Groot JF, Sol M.

Pediatr Phys Ther. 2019 Apr;31(2):191. doi: 10.1097/PEP.0000000000000600. No abstract available.

PMID:
30907837
9.

Children and Teens in Charge of their Health (CATCH): A protocol for a feasibility randomised controlled trial of solution-focused coaching to foster healthy lifestyles in childhood disability.

McPherson AC, Biddiss E, Chen L, Church PT, de Groot JF, Keenan S, King G, Lui T, Maltais DB, Mérette C, Moffet H, Moola F, Schwellnus H.

BMJ Open. 2019 Mar 4;9(3):e025119. doi: 10.1136/bmjopen-2018-025119.

10.

Physical exercise training for type 3 spinal muscular atrophy.

Bartels B, Montes J, van der Pol WL, de Groot JF.

Cochrane Database Syst Rev. 2019 Mar 1;3:CD012120. doi: 10.1002/14651858.CD012120.pub2. Review.

PMID:
30821348
11.

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM.

Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11.

PMID:
30742122
12.

Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests.

Bartels B, Habets LE, Stam M, Wadman RI, Wijngaarde CA, Schoenmakers MAGC, Takken T, Hulzebos EHJ, van der Pol WL, de Groot JF.

BMC Neurol. 2019 Feb 9;19(1):21. doi: 10.1186/s12883-019-1244-3.

13.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

14.

Fitkids Treadmill Test: Clinical Utility and Factors Associated With Its Use Among Physical Therapists.

Kotte EMW, de Groot JF, Winkler AMF, Veenhof C, Takken T.

Phys Ther. 2019 Apr 1;99(4):428-439. doi: 10.1093/ptj/pzy142.

PMID:
30690630
15.

Effect of health disparities on overall survival of patients with glioblastoma.

Mandel JJ, Youssef M, Nam J, Patel AJ, Jalali A, Ludmir EB, Liu D, Wu J, Armstrong G, Huse J, Bondy M, de Groot JF.

J Neurooncol. 2019 Apr;142(2):365-374. doi: 10.1007/s11060-019-03108-z. Epub 2019 Jan 22.

PMID:
30671709
16.

A Novel Tool for Quantifying and Promoting Physical Activity in Youths With Typical Development and Youths Who Are Ambulatory and Have Motor Disability.

Lankhorst K, van den Berg-Emons RJ, Bussmann JBJ, Horemans HLD, de Groot JF.

Phys Ther. 2019 Mar 1;99(3):354-363. doi: 10.1093/ptj/pzy152.

PMID:
30649497
17.

Physical activity in wheelchair-using youth with spina bifida: an observational study.

Bloemen MAT, van den Berg-Emons RJG, Tuijt M, Nooijen CFJ, Takken T, Backx FJG, Vos M, de Groot JF.

J Neuroeng Rehabil. 2019 Jan 14;16(1):9. doi: 10.1186/s12984-018-0464-x.

18.

Effects of High-Intensity Interval Training on Fitness and Health in Youth With Physical Disabilities.

Zwinkels M, Verschuren O, de Groot JF, Backx FJG, Wittink H, Visser-Meily A, Takken T; Sport-2-Stay-Fit study group.

Pediatr Phys Ther. 2019 Jan;31(1):84-93. doi: 10.1097/PEP.0000000000000560.

PMID:
30507854
19.

Disparities along the glioblastoma clinical trials landscape.

Ludmir EB, Mandel JJ, McAleer MF, de Groot JF.

Neuro Oncol. 2019 Feb 14;21(2):285-286. doi: 10.1093/neuonc/noy176. No abstract available.

20.

Lower-grade gliomas: the wrong target for bevacizumab.

Schiff D, de Groot JF.

Neuro Oncol. 2018 Nov 12;20(12):1559-1560. doi: 10.1093/neuonc/noy165. No abstract available.

PMID:
30418659
21.

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M.

Cancer. 2019 Feb 1;125(3):424-433. doi: 10.1002/cncr.31811. Epub 2018 Oct 25. Erratum in: Cancer. 2019 Apr 15;125(8):1387.

PMID:
30359477
22.

The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study.

Ding X, Wang Z, Chen D, Wang Y, Zhao Z, Sun C, Chen D, Tang C, Xiong J, Chen L, Yao Z, Liu Y, Wang X, Cahill DP, de Groot JF, Jiang T, Yao Y, Zhou L.

J Neurooncol. 2018 Dec;140(3):591-603. doi: 10.1007/s11060-018-2985-3. Epub 2018 Sep 11.

PMID:
30206763
23.

Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).

Stam M, Wadman RI, Wijngaarde CA, Bartels B, Asselman FL, Otto LAM, Goedee HS, Habets LE, de Groot JF, Schoenmakers MAGC, Cuppen I, van den Berg LH, van der Pol WL.

BMJ Open. 2018 Jul 30;8(7):e019932. doi: 10.1136/bmjopen-2017-019932.

24.

A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models.

Zinn PO, Singh SK, Kotrotsou A, Hassan I, Thomas G, Luedi MM, Elakkad A, Elshafeey N, Idris T, Mosley J, Gumin J, Fuller GN, de Groot JF, Baladandayuthapani V, Sulman EP, Kumar AJ, Sawaya R, Lang FF, Piwnica-Worms D, Colen RR.

Clin Cancer Res. 2018 Dec 15;24(24):6288-6299. doi: 10.1158/1078-0432.CCR-17-3420. Epub 2018 Jul 27.

PMID:
30054278
25.

Treatment of Glioblastoma in the Elderly.

Harrison RA, de Groot JF.

Drugs Aging. 2018 Aug;35(8):707-718. doi: 10.1007/s40266-018-0568-9. Review.

PMID:
30039343
26.

Highlighting the need for reliable clinical trials in glioblastoma.

Mandel JJ, Youssef M, Ludmir E, Yust-Katz S, Patel AJ, De Groot JF.

Expert Rev Anticancer Ther. 2018 Oct;18(10):1031-1040. doi: 10.1080/14737140.2018.1496824. Epub 2018 Jul 12. Review.

PMID:
29973092
27.

An inhibitor of oxidative phosphorylation exploits cancer vulnerability.

Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR.

Nat Med. 2018 Jul;24(7):1036-1046. doi: 10.1038/s41591-018-0052-4. Epub 2018 Jun 11.

PMID:
29892070
28.

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.

Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, Mehta S, Gatalica Z, Swensen J, Sanai N, Spetzler D, Heimberger AB.

J Neuropathol Exp Neurol. 2018 Jun 1;77(6):437-442. doi: 10.1093/jnen/nly022.

29.

Implementing paediatric early warning scores systems in the Netherlands: future implications.

de Groot JF, Damen N, de Loos E, van de Steeg L, Koopmans L, Rosias P, Bruijn M, Goorhuis J, Wagner C.

BMC Pediatr. 2018 Apr 6;18(1):128. doi: 10.1186/s12887-018-1099-6.

30.

Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome.

Kotrotsou A, Elakkad A, Sun J, Thomas GA, Yang D, Abrol S, Wei W, Weinberg JS, Bakhtiari AS, Kircher MF, Luedi MM, de Groot JF, Sawaya R, Kumar AJ, Zinn PO, Colen RR.

J Neurooncol. 2018 Aug;139(1):125-133. doi: 10.1007/s11060-018-2850-4. Epub 2018 Apr 4.

PMID:
29619649
31.

The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.

Dong J, Park SY, Nguyen N, Ezhilarasan R, Martinez-Ledesma E, Wu S, Henry V, Piao Y, Tiao N, Brunell D, Stephan C, Verhaak R, Sulman E, Balasubramaniyan V, de Groot JF.

Oncotarget. 2018 Jan 8;9(12):10497-10509. doi: 10.18632/oncotarget.24041. eCollection 2018 Feb 13.

32.

Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma.

Piao Y, Henry V, Tiao N, Park SY, Martinez-Ledesma J, Dong JW, Balasubramaniyan V, de Groot JF.

Oncotarget. 2017 Jun 29;8(57):96970-96983. doi: 10.18632/oncotarget.18859. eCollection 2017 Nov 14.

33.

A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma.

Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP.

Oncotarget. 2017 Oct 12;8(52):90488-90495. doi: 10.18632/oncotarget.21799. eCollection 2017 Oct 27.

34.

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD.

Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26.

35.

Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis.

Lee JH, Liu R, Li J, Zhang C, Wang Y, Cai Q, Qian X, Xia Y, Zheng Y, Piao Y, Chen Q, de Groot JF, Jiang T, Lu Z.

Nat Commun. 2017 Oct 16;8(1):949. doi: 10.1038/s41467-017-00906-9.

36.

Wheelchair Shuttle Test for Assessing Aerobic Fitness in Youth With Spina Bifida: Validity and Reliability.

Bloemen MAT, de Groot JF, Backx FJG, Benner J, Kruitwagen CLJJ, Takken T.

Phys Ther. 2017 Oct 1;97(10):1020-1029. doi: 10.1093/ptj/pzx075.

37.

Treatment of Glioblastoma.

Nam JY, de Groot JF.

J Oncol Pract. 2017 Oct;13(10):629-638. doi: 10.1200/JOP.2017.025536. Review.

PMID:
29020535
38.

Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.

Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, Yuan Y, Kent TA, de Groot JF.

Neuro Oncol. 2018 Jan 10;20(1):113-122. doi: 10.1093/neuonc/nox144.

39.

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ.

Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Review.

PMID:
28925994
40.

Development of a wheelchair mobility skills test for children and adolescents: combining evidence with clinical expertise.

Sol ME, Verschuren O, de Groot L, de Groot JF; Fit-For-the-Future!-consortium.

BMC Pediatr. 2017 Feb 13;17(1):51. doi: 10.1186/s12887-017-0809-9. Review.

41.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS.

J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1. No abstract available.

PMID:
28148207
42.

Cell Signaling Pathways in Brain Tumors.

Harrison RA, de Groot JF.

Top Magn Reson Imaging. 2017 Feb;26(1):15-26. doi: 10.1097/RMR.0000000000000112. Review.

PMID:
28079711
43.

Fitkids Treadmill Test: Age- and Sex-Related Normative Values in Dutch Children and Adolescents.

Kotte EM, de Groot JF, Bongers BC, Winkler AM, Takken T.

Phys Ther. 2016 Nov;96(11):1764-1772. Epub 2016 May 19.

PMID:
27197825
44.

Validity and Reliability of Skill-Related Fitness Tests for Wheelchair-Using Youth With Spina Bifida.

Bloemen MA, Takken T, Backx FJ, Vos M, Kruitwagen CL, de Groot JF.

Arch Phys Med Rehabil. 2017 Jun;98(6):1097-1103. doi: 10.1016/j.apmr.2016.08.469. Epub 2016 Sep 12.

45.

Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.

O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT.

J Neurooncol. 2016 Dec;130(3):495-503. Epub 2016 Aug 30.

PMID:
27576699
46.

Prioritization schema for immunotherapy clinical trials in glioblastoma.

Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB.

Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Review.

47.

A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.

Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF.

J Neurooncol. 2016 Sep;129(3):487-494. doi: 10.1007/s11060-016-2195-9. Epub 2016 Jul 12.

48.

Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models.

Park SY, Piao Y, Jeong KJ, Dong J, de Groot JF.

Mol Cancer Ther. 2016 Sep;15(9):2187-97. doi: 10.1158/1535-7163.MCT-15-0427. Epub 2016 Jun 15.

49.

Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.

Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF.

J Neurooncol. 2016 Aug;129(1):147-54. doi: 10.1007/s11060-016-2157-2. Epub 2016 Jun 7.

50.

Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma.

Park SY, Piao Y, Thomas C, Fuller GN, de Groot JF.

Oncotarget. 2016 May 3;7(18):26793-805. doi: 10.18632/oncotarget.8471.

Supplemental Content

Loading ...
Support Center